Emerging Nanomedicines for the Treatment of Atopic Dermatitis

Abstract

Globally, the prevalence of Atopic dermatitis (AD) is significantly increasing and affecting around 20% of population including children. Complex interactions amongst abnormality in epidermal barrier function, environment, infectious agents and immunological defects are considered as key factors in the pathogenesis of AD. Although the role of oxidative stress has been studied in some skin diseases, investigation of the same in AD is intermittent. Calcineurin inhibitors and/or topical corticosteroids are currently available; however, it causes atrophy of the skin, burning sensation, and systemic side effects which leads to poor patient compliance. These limitations provoke the strong need to develop an innovative approach in managing AD. Nanomaterials for effective drug delivery to skin conditions such as AD have attracted a lot of attention owing to its ability to encapsulate, protect, and release the cargo at the diseased skin site. However, there are lots of unmet challenges especially in terms of development of non-toxic formulations and clinical translation of established nanomedicines in the form of accessible products. Numerous formulations have emerged as carrier for poorly soluble and permeable drugs, viz., lipidic, polymeric, metal, silica, liposomes, hydrocarbon gels and this field is evolving. This review is intended to provide an insight incidences associated with pathophysiology of AD and challenges with existing treatments of AD. Focus is kept on reviewing current development and emerging nanomedicines for effective treatment of AD. The review also inculcates merits of several nanomedicines in overcoming challenges of existing products and its future implications.

INTRODUCTION

Atopic dermatitis (AD) is a very common skin disease with chronic and relapsing immunological abnormalities in the skin (1,2) characterized by recurrent eczematous lesions and intense itch. AD is a potentially enervating skin disease which demonstrates substantial socioeconomic influence on mankind worldwide (3). The phrase AD is a combination of two syndromes, i.e., atopy and dermatitis. Coca and Cooke invented the term “atopy” in 1923, which is directly related with IgE-mediated reaction. Before the development of hypersensitivity reaction, there might be exposure to an allergen, although it involves a genetic component (4). Atopy can be present as asymptomatic sensation in any form of the disease like AD, fever, and asthma. Redness, swelling, and skin soreness are linked with the development of dermatitis. The presence of small blisters are observed due to direct irritation by an external allergen (5). AD is also known as “Prurigo Besnier (Besnier’s itch) over the years, named after the French dermatologist Ernest Besnier (1831–1909).”

Distinctive symptoms of AD include mild to severe erythema, scaling, and excoriations to acute flare ups of eczematous pruritic lesions and intense itch (6). In AD, skin becomes red, brownish, dry, scaly or cracked, and itchy due to decrease in the hydration of stratum corneum. This condition is mainly observed at night (6,7). In infants, AD is manifested as an eczema associated with tiny bumps on the cheeks, where in the case of children and adults, it is observed often as rashes in the joint folds, on the rear part of the hands and often on the scalp (7). History of typical sequence of AD in the childhood indicates the initial step of the “atopic march” and often remits the chances of allergic disorder development in the later phase of life. This term is also known as “allergic march” (8). The prevalence of AD is increasing day by day, and literature shows rising number of patients suffering from AD during the past decade (9). Treatment of skin diseases using topical formulations is being accepted widely because very less concentration of the drug is absorbed systemically which ultimately reduces the side effects as compared to the conventional (parenteral or oral) drug administration. Currently available topical treatments have limited penetration into the deeper layers of the skin due altered skin condition during AD. This provoked the need to develop novel formulations with enhanced penetration into the deeper layers of the skin, i.e., epidermis, and provide more effective local drug release with low systemic toxicity. Moreover, the ability of the formulation to encapsulate various hydrophobic anti-inflammatory drugs is also considered a challenge especially when hydrophilic topical dosage forms are used in the treatment of atopic dermatitis. Therefore, a lot of efforts have been devoted in development of new carriers including nanoparticles for the treatment of AD. This review is aimed to provide an insight on incidences associated with pathophysiology of AD and challenges with existing treatments of AD. It also includes review of current development and emerging nanomedicines for effective treatment of AD.

Epidemiology

A study on distribution and regional variance in the occurrence of AD was performed internationally on 1 million subjects with three different phases (10). The prevalence of AD and the region where highest prevalence of AD is found vary continuously around the world. It was found that around 1/4th of the world population is affected by AD during their lifespan. Between 1950 and 2000, the prevalence of AD increased approximately up to threefolds mainly in so called industrialized countries that it was referred as “allergic epidemic” (6,11). However, eczema symptoms have been settled or reduced in some countries having huge prevalence. Nigeria, the UK, and New Zealand were the region of maximum prevalence previously; however, Latin America is now leading as most prevalent region for AD (12). Nevertheless, AD is a major health concern and the disease is still augmenting particularly in the developing world. During last few years, quite high occurrence of AD has been observed in India and it was the most common amongst children (13).

Natural history of AD suggests that almost 50% of influenced patients develop characteristic features within initial years of life and probably 95% experience an onset at the age below five (12). Around 75% with onset of AD early in the life have an extemporaneous retardation before adolescence, whereas the rest of 25% will continue experiencing a relapse of disease symptoms after few years with temporary recovery. Rare cause of exacerbations in AD may be food intake or contact with airborne allergens (14,15). The chances of developing AD are more prominent in those having family history of occurrence of the disease. For example, if the cotwin is affected, the risk of the disease increases by 75% and 30% in the case of monozygotic and dizygotic twins respectively. This shows that susceptibility of AD has correlation with genetic factors (16,17).

Increased prevalence of AD in the past few years has enforced a high socioeconomic burden in many developing countries in terms of medical management and patients’ living standards. As a result, there has been an intensified interest in distinguishing environmental threats and precautionary measures (6).

According to the Global Burden of Disease survey 2010 conducted by The World Health Organization (WHO), AD was ranked first amongst common dermal diseases in terms of “life-years adjusted with disability” and “years lived with a disease” (8).

Pathogenesis

The researchers are unsure about the pathogenesis of AD for decades. There is still a lacuna in revealing consolidated proof of concept of AD. By elucidating the mechanism of occurrence of AD in inherently susceptible individuals, researchers have already achieved a salient milestone. Histology reveals the presence of eosinophils, macrophages, and T cells in the case of relapsing itch and inflammation (observed as overgrowth of dermis and epidermis) in AD (6). Pathophysiology of atopic dermatitis is described in Fig. 1.

Fig. 1
figure1

Pathophysiology of atopic dermatitis [reproduced from reference (18)]

Overall, multiple factors are affecting the development of AD which includes multifaceted interactions amongst ecological factors, defective epidermal barrier function, and susceptibility genes (19). The primary cause of AD is an abnormal skin barrier due to mechanical injury as a result of scratching which aggravates dry itchy skin. It is proven that the inherent and adaptive immune system interactions have a role to play in the AD pathological indications (20).

In recent years, the role of oxidative stress (OS) is being studied in the pathogenesis of AD. It is very well in knowledge that due to OS, genes coded for proinflammatory cytokines are up regulated which in turn promote tissue inflammation. Release of free radicals takes place from inflammatory cells when activated. From its prominent inflammatory compound, OS could be considered as one of the key role players in pathogenesis of AD (21). Factors influencing the pathogenesis of AD are described in Fig. 2.

Fig. 2
figure2

Factors influencing the pathogenesis of atopic dermatitis

Inflammatory lesions in AD are explained by two hypotheses: (i) imbalance in the adaptive immune system and (ii) abnormal skin barrier. The proposed two hypotheses may complement each other although they are not totally unrelated.

Immunological Hypothesis

According to the theory of immunological inequity, it is claimed that imbalance of particularly 1, 2, 17, and 22 type of T helper cell and regulatory T cells causes AD (19). In acute eczema, the state of allergic (atopic dermatitis) predominance of the naive CD4+ T cells as a result of Th2 differentiation is observed resulting into the enhancement in the generation of interleukins, viz., IL-4, IL-5, and IL-13, which are responsible for improved levels of IgE. Correspondingly, inhibition of Th1 differentiation also takes place.

The Skin Barrier Hypothesis

According to this theory, reduced level of filaggrin and ceramides in the epidermis, a classical representation of inherited and acquired barrier function, is considered as the prime pathogenesis of AD (22,23,24). Normally, structural proteins of stratum corneum (SC) and stratum granulosum are encoded by filaggrin gene. This protein helps in binding the keratinocytes together and maintaining the integral skin barrier. It also plays role in stratum corneum hydration. With the faulty gene, filaggrin production is reduced which leads to trans epidermal water loss (TEWL) and eczema. Barrier defects weaken the protective function of the epidermis against irritant substances responsible for aggravating the disease. Additionally, inhaled allergens penetrate into the epidermis due to retarded barrier function of SC and thereby they may contribute to aggravate AD (25,26).

Interestingly, in AD, immunological imbalance and skin barrier abnormality present a cause and effect dilemma. Due to disturbed epidermal barrier function and dryness, skin becomes more susceptible for the internalization of numerous allergens and irritants into the skin along with other adverse environmental factors. This action triggers and provokes allergy with one more episode of inflammation (27,28). Barrier integrity can be altered by inflammation itself. Therefore, dry skin is one of the most prominent factor in damaging the skin and also contributes in pathogenesis of AD (29). It could be said that barrier function restoration is essential while designing prevention plan and aggravation of AD (30).

CURRENT STANDPOINT OF THE TREATMENTS FOR ATOPIC DERMATITIS

Due to lack of complete cure of AD; several patients experience a prolonged duration of the disease. The therapies include prevention of disease by reducing number of flares and reduction in relapse. Severity of flares are reduced by treatment with topical corticosteroids and/or topical calcineurin inhibitors.

The primary and secondary prevention includes delayed exposure to antigens. Food avoidance and prevention of AD have a direct relationship between them and its influence is still unclear (31); however, sensitization to food allergens is associated with infantile AD (32). Reports have shown that involvement of hydrolyzed or amino acid-based products in management of AD is significant (33).

Tertiary prevention can be achieved by diminishing the dryness of the skin, principally by means of daily utilization of skin-hydrating agents like cream or emollients. Care should be taken towards exposure to unknown irritants, like allergens and synthetic fiber-based clothing are avoided. Emollients do not have direct effect during eczema. Furthermore, skin dryness can be prevented by avoiding long, hot baths. Use of an emollient is endorsed for maintenance of hydrated epidermis and boost the function of epidermal barrier.

Currently Available Formulations and their Limitations

Many countries follow an agreement published as series of guidelines regarding the treatment of AD (34,35). Guidelines are meant to help pediatricians and dermatologists in management of many patients with AD (36) which also contributes in improving their wellbeing. However, therapeutic management may get failed sometimes in patients with AD, especially in the case of prolonged treatment. The main problems are socioeconomic complications, severity, and extent of activity of AD. It is thus expected that innovation in the treatment of AD will be essential. Table I covers currently available therapies for management and the treatment of the AD.

Table I Currently Available Conventional Dosage Forms for the Treatment of AD (37)

Currently, treatment of AD is managed by “reactive management” strategy which consists of combative response to acute flare-up incidents alongside topical agents falling in an anti-inflammatory category. However, acanthosis and perivascular lymphatic infiltration are seen histologically or as subclinical inflammatory change in the normal-appearing skin. Hence, normal-appearing skin is still a target for anti-inflammatory drug. This treatment is further continued with another therapeutic treatment and use of anti-inflammatory drugs intermittently which is known as “proactive treatment.” But these therapies may not be effective in all the patients (38).

Moreover, creams, ointments, and lotions like formulation contain oily vehicle and leave sticky residue on the skin. Bioavailability of drugs on the skin varies as skin is least perfused amongst all the tissues. Some secondary infection may be sub lying in the deeper layer of the skin and gives false symptomatic relief on the skin. Targeting deeper layer of the skin is also difficult due to protective barrier. Also, issue of poor penetration of the drug in the skin persists with the diseased condition.

Ongoing Clinical Trials

Although there are limitations with currently available therapies, they are treating the disease in current scenario. Research have been done for incorporation of various new molecules in the conventional dosage forms. Table II comprises of few clinical trials being done with different molecules for more effective treatment of AD. If these products pass the clinical trials successfully, many products with better effectiveness will acquire the market in near future.

Table II Details of Clinical Trials Being Done for the Treatment of Atopic Dermatitis (39)

Issues associated with currently available treatments indicate a compelling need for the development of novel formulations which can overcome the shortcomings of conventional therapies. In the following sections, we have reviewed nanomedicine as one of the emerging technologies for improving drug delivery to skin with a particular focus on AD.

NANOMEDICINES FOR ATOPIC DERMATITIS—CURRENT SCENARIO

Topical corticosteroids are considered as the first-line treatment of AD. They have anti-inflammatory and anti-proliferative actions which are responsible for their therapeutic effect as well as side effects like skin atrophy (skin thinning), telangiectasia, and skin burning. Topical steroids inhibits the enzyme phospholipase A2 by synthesizing lipocortin. Inflammation is caused when phospholipase A2 release arachidonic acid from the cell membrane. The inhibition of phospholipase A2 results in the reduction of inflammation. This inhibitory actions affect the keratinocyte proliferation, fibroblasts, and hyaluronan synthase 3 enzyme resulting in the reduction of hyaluronic acid in the extracellular matrix leading to dermal atrophy. These side effects are associated with long-term use of topical steroids (40). Hence, these agents are suitable to use for short-term therapy only (35,41). The growth of nano-intervention-based drug delivery is rapidly growing along with impending applications in healthcare and drug nanoplatform-based delivery sector. The skin provides inherent protection against entry of foreign particles, although therapeutic NPs can be delivered in affected areas of the skin via hair follicle openings. Potential of NP-based drug delivery needs to be understood deeply although it has been publicized as a facilitating technology in the treatment of local diseases. Mechanisms related to the explanation of infiltration and preservation of NPs across the epidermal barrier have been thoroughly discussed. One study result suggests that rate of drug release in the dermal layers may be controlled by incorporating the drug NP into the lipid matrix to achieve therapeutic efficacy (42). There are several distinct properties of nanoparticles, viz., surface properties, charge, shape, and size, that can affect the release rate and skin penetration. Furthermore, when NPs are delivered topically, they are expected to retain in the skin. Hence, the study of degree and rate of infiltration of NPs is important to get idea about the interactions of NPs with physiological fluids and thereby their entry into the systemic circulation (43). Figure 3 is a representation of various mechanisms by which NPs are delivered to the skin. Solid lipid nanoparticles (SLN), nanolipid carriers (NLCs) (44), and nanoemulsions and microemulsions (45) are few lipid-based systems which have been explored for topical drug delivery. Other than these systems, polymeric nanoparticles and liposomes have also been explored as an alternative drug delivery system for topical route (46,47).

Fig. 3
figure3

Various mechanisms for dermal delivery of NPs. a Anatomy of the skin and b routes of drug penetration (reproduced from reference (48))

Polymer-Based Nanoparticles

Polymeric NPs have various characteristic features such as biodegradability, biocompatibility, low particle size, and greater surface charge for stability which are attractive for its use for topical delivery. More specifically, polymeric NPs have been used with several drugs for the treatment of AD, owing to their exceptional properties such as greater entrapment efficiency and sustained release, physiological stimuli-responsive nature, enzymatic degradation prevention, and targeting specific site which minimize off targeting effects.

For instance, Zhuo et al. (49) fabricated hyaluronic acid-decorated tacrolimus-loaded chitosan NPs (HA@TCL-CSNPs) with aim to maximize the dermal targeting and enhance anti-dermatitis efficiency. The results indicated that particle size, zeta potential, and entrapment efficiency (%EE) of optimized TCL-CSNPs were found to be 156 nm, +53 mV, and 84.11%, respectively. The surface charge, average particle size, and entrapment efficiency (%EE) of optimized HA@TCL-CSNPs were found to be 216 nm, +34 mV, and 57.14%, respectively. The size was increased due to coating of HA onto the CSNPs, whereas zeta potential decreased due to the negatively charged HA. Furthermore, the release study confirmed that after 8 h, TCL-CSNPs and HA@TCL-CSNPs showed 75% and 25% of drug release. This phenomenon occurred owing to the presence of HA as HA prevents or acts as a barrier for the release of TCL. Additionally, HA may restrict the diffusion of water into the polymer matrix which consequently retards the release rate of TCL. Additionally, HA@TCL-CSNPs demonstrated greater efficiency in the maintenance of intact skin throughout the period of induction and treatment and displayed minimum symptoms of erythema and dryness as compared to TCL-CSNPs. It may be owing to the optimal localization of TCL into dermis and epidermis. Histopathological study demonstrated that HA@TCL-CSNPs restored the skin integrity in the mice and found to be safe.

In the similar manner, Pandey et al. (50) formulated HA-coated betamethasone valerate (BMV)–loaded CSNPs (HA@BMV-CSNPs) for dermal targeting and enhance penetration across the stratum corneum. The results indicated that particle size, zeta potential, and %EE of optimized HA@BMV-CSNPs were found to be less than 300 nm, +58 mV, and 86%, respectively. The in vitro release investigation demonstrated that HA@BMV-CSNPs showed Fickian diffusion–type release mechanism in simulated skin surface (pH 5.5). The permeation study concluded that as compared to HA@BMV-CSNPs, BMV from BMV-CSNPs was significantly permeated through the skin. However, more dermal retention was observed for BMV in the case of HA@BMV-CSNPs as compared to BMV-CSNPs. Furthermore, Try et al. (51) studied the effect of size of NPs on skin penetration in dermatitis models such as porcine and murine. For the same, the researchers developed PLGA NPs with two different sizes, i.e., 70 nm and 300 nm. The results indicated that no skin penetration was found in the case of healthy skin. However, PLGA NPs with particle size of 70 nm was significantly accumulated higher (15-folds in mice and fivefolds in pig) in the inflamed skin as compared to PLGA NPs with 300 nm of size. Additionally, penetration depth study revealed that in pig skin model, PLGA NPs with 70 nm size were found to be greatly penetrated (46 μm) as compared to PLGA NPs with particle size of 300 nm (23 μm). However, in mice skin, both size of PLGA NPs demonstrated similar penetration depth 55 μm, but the penetration depth of NPs decreased over the time in mice to 20 μm.

Moreover, Siddique et al. (52) developed a cream containing hydroxytyrosol (HT) and hydrocortisone (HC)-loaded CSNPs for safe and tolerable efficacy of NPs in potential treatment of AD. The results revealed that optimized size of HC/HT CSNPs was less than 250 nm and cream of HC/HT CSNPs was found to be stable when stored at 25°C. Furthermore, erythema intensity transepidermal water loss (TEWL) for 28-day application did not display any signs of redness, local irritation, and toxicity. In addition to this, the similar results were obtained for biochemistry of blood, blood hematology, and adrenal cortico-thyroid hormone level at 0 and 28 days. Thus, from the aforementioned results, it can be concluded that HC/HT CSNP cream is safe and well tolerated, which can be beneficial in the treatment of AD. Furthermore, considering the stimuli-responsive delivery system can be an effective platform for dermal application.

Sahle et al. (53) fabricated various types of pH-responsive dexamethasone-loaded Eudragit® L 100, Eudragit® L 100-55, Eudragit® S 100, HPMCP-50, HPMCP-55, and cellulose acetate phthalate NPs and fabricated using nanoprecipitation method (54). The results indicated that cellulose acetate phthalate NPs were found to be more pH responsive as compared to other NPs. Cellulose acetate phthalate NPs when dissolved in 10 mM pH 7.5 buffer found that greater than 80% of the drug was released within 7 h, whereas acrylate NPs when dissolved in 40 mM pH 7.5 buffer found that 65–70% of the drug was released after 7 h. The study also concluded that properties of NPs and their release pattern can be modulated by blending various polymers and all formulations were found to be safe.

Additionally, Katas et al. (55) investigated for histological stabilization and immune-modulatory effects of HT/HC co-loaded CSNPs via transcutaneously using NC/Nga mouse model. The ex vivo study confirmed that skin thickness of AD-induced CSNP-treated mice (456 μm) was significantly reduced as compared to atopic mice (916 μm). Immune spectrum analysis revealed that HT/HC CSNPs were capable of restraining immunoglobulin E (IgE), histamine, T helper cells (TH1/TH2), VEGF-α, and prostaglandin E2 (PGE2)–producing cytokines in serum and skin biopsies of tested mice. In the similar manner, Hussain again investigated the downregulation of immunological mediators using HC-loaded CSNPs in 2,4-dinitrofluorobenzene-induced AD-like skin lesion. The analysis of expression of cytokine in AD-like skin lesion indicated that HC CSNPs inhibited the pathological expression of TNF-α, interferon-γ, IL-4, IL-5, IL-6, IL-12p70, and IL-13. Additionally, histological study demonstrated that HC CSNPs inhibited fragmentation of elastic fibers and fibroblast infiltration.

Yu et al. (56) explored the development of a hybrid skin-targeting nano system with nicotinamide (NIC) and chitosan NP (CS@NP) for encapsulating Tacrolimus (FK506), i.e., FK506@NIC@CSNP, for the treatment of dermatitis. Results showed that FK506 containing NIC@CSNP has significantly enhanced penetration and deposition into the skin as compared to Protopic®. The results of efficacy studies of the clinical symptoms in animal model of AD demonstrated that approximately 1/3rd dose of NIC@CSNP was superior to that of Protopic alone. The adjuvant therapeutic response and anti-AD effects to moderate level were observed with NIC–CS–NP vehicle. Ghosh et al. (57) studied the efficacy of guar gum nanoparticles (GN) in AD on BALB/c mice. Disease-induced mice were treated topically with GN. Ear thickness was found significantly reduced on the 28th day. After the application of GN on the skin, the total cell count, eosinophil count, and Th cell and macrophage populations were decreased and the same was confirmed by histological studies. Cellular infiltration and epidermal thickness were reduced in ear tissue after the treatment. Efficacy enhancement of hydrocortisone acetate was studied in synthetic polymeric nanoparticles. Rosado et al. used solvent displacement method in preparation of the hydrocortisone acetate (HCA)–loaded poly (ε-caprolactone (PCL) nanoparticles (NPs) to achieve a prolonged release of drug and reduction of side effects. It was confirmed that the developed formulation indicated minimum side effects and increased its therapeutic efficacy (58).

Lipid-Based Nanoparticles

It has been known for a long time that lipid-based NPs such as solid lipid NPs (SLNPs) and nanostructured lipid carriers (NLCs) have been extensively studied by the researchers for topical delivery, owing to their ability to load both hydrophilic and/or lipophilic therapeutic moieties (44). Additionally, the carriers mimicking physiological lipids have been attracted lot of researchers owing to their higher biocompatibility, biodegradability, and follicle delivery. They have the capability to release the drug in a controlled manner and provide greater occlusion which in turn is responsible for improved skin hydration (59). However, NLCs are far better than SLNs as it overcomes the disadvantages of SLNs such as leaking of drug/therapeutic moiety during storage caused by lipid polymorphism, risk of gelation, and limited drug loading (60). NLCs are formed by utilizing solid lipid and liquid lipid which ultimately forms the less perfect crystalline structure with many imperfections providing more space for drug accommodation (61,62). Many studies came to conclusion that small-size lipid carrier ensures close contact to the stratum corneum and can improve penetration of therapeutic moiety into the skin (63,64). The epidermal targeting may be exploited using NLCs and SLNs as well as reduction of side effects can be achieved. Potential side effects due to systemic absorption of topical corticosteroids (atrophy, skin thinning) can also be eliminated using such carriers. SLNs have also demonstrated to facilitate therapeutic moiety retention in the upper layer of skin and to obtain occlusion, which occurs owing to the strong adhesion properties of nanocarrier and small size, leading to the formation of the film on the skin and reduce the TEWL by helping in restoration of the physical barrier (65).

Pople and Singh (30) explored the high-pressure homogenization technique in the development of tacrolimus-loaded modified NLC (T-MNLC) with an aim to enhance its solubility. They used lipophilic solubilizer in carrier lipid matrix for drug delivery to the skin. T-MNLC formulation was found stable with reduced total lipid concentration in carrier. Thus, the study highlighted that novel T-MNLC prepared using lipophilic solubilizers were very useful in terms of performance, and improved stability and skin retention. Pople and Singh also studied the skin hydration properties, targeted delivery, therapeutic effectiveness, and toxicity of modified nanolipid carrier. The enhanced targeting and therapeutic efficacy were studied on in vivo model for AD-like skin lesions in BALB/c mice. Moreover, improved safety was observed with T-MNLC-treated group. Thus, it indicates that novel T-MNLC formulation would get wide acceptance by the patients to treat large skin areas of AD with chronic treatment regimen (66).

Maia et al. (67) investigated SLN to increase targeting to the viable epidermis. SLN of a topical glucocorticoid prednicarbate (PC) were developed which penetrates almost 30% greater into human skin as compared to PC cream. This may possibly because of particle size and close interaction of SLNs with the stratum corneum. Biotransformation of PC did not change by SLN incorporation and the same was confirmed by penetration study of prednicarbate PC-SLNs. A threefold increase in PC permeation after incorporation into SLNs was reported.

Fang et al. (68) proposed use of betamethasone dipropionate (BD)–loaded NLCs (BD-NLC) in topical ointment formulation for the treatment of AD. In vitro drug release results of BD-NLC suggest better skin localization using without ointment. No evidence of skin irritation was observed during in vivo studies using rabbits. Moreover, the self-made topical ointment exhibited required drug retention in skin tissue of living mice. This study accentuated the development of BD-NLC as a potential therapy with reduction in adverse effects induced by systemic absorption.

Elastic liposomes were developed for taxifolin glycoside (TXG) to be delivered to the skin. Pep-1 peptides were exposed to thiolmaleimide reaction for conjugation to drug containing elastic liposome. Prepared formulation was examined for efficacy and skin permeation. Hence, TXG-loaded Pep1-EL preparations can be considered as effective measure for the treatment of AD (69). Nanonization is one of the approaches to improve solubility; hence, nanomedicines are most explored for hydrophobic drugs. Lipid-based nanoformulations are widely explored as compared to other approaches and due to high affinity of the lipids with skin. These formulations have proven to be more promising.

Micro-nano Emulsions

Emulsion-based systems are obtained using two or more immiscible liquids, where one is dispersed phase, and another is dispersion medium. Emulsion-based systems possess certain merits such as ease of scale-up with cost effectiveness and ease of formation and sterilization. However, some disadvantages of this method are complex and time-consuming development process, phase inversion, drug leakage, and surfactant-/co-surfactant-related toxicity. It has an ability to incorporate and enhance penetration of both hydrophilic and/or lipophilic therapeutic moieties. Therapeutic moieties having higher solubility are categorized to this performance as they enhance the concentration gradient towards the skin. Mechanism of surfactant within the vehicle is penetration enhancer as well as internal mobility modulator also contributes to the effective performance of emulsion in skin delivery. The release of therapeutic moiety from the emulsion depends on the interaction between surfactant and therapeutic moiety or/and partitioning of therapeutic moiety in water and oil phase. In the view to above discussion, Baspinar et al. (70) developed positively charged prednicarbate nanoemulsion with physical and chemical stability for the treatment of AD. Use of positively charged carrier is helpful in dermal delivery, as adsorption of the same onto the negatively charged skin. This increases the retention time and thus the availability of the drug at targeted region. A microemulsion cream formulation of tacrolimus was developed and compared against ointment in hapten-induced murine model of dermatitis which enhanced the penetration through skin. The penetration enhancement was consigned to the possibility of dose reduction. The results of developed cream was confirmed by in vivo studies and it was found that the formulation significantly reduces expression of cytokine by more deposition in the targeted site (71).

Alam et al. (72) developed the clobetasol propionate (CP) topical oil-in-water (o/w) nanoemulsion using aqueous phase titration method. Anti-inflammatory activity of CP-loaded nanoemulsion was improved. There was a significant increase in nucleoside triphosphate diphosphohydrolases activity in lymphocytes. Use of high amount of surfactant was proven safe by skin irritation studies on animal model and hence proved safe for human use.

Yang et al. (73) did comparative studies of triptolide (TPL) nanoemulsions and nanoemulsion-based gel of TPL to check their effect on percutaneous permeation enhancement. TPL nanoemulsion gels and TPL nanoemulsion showed better penetration as compared to TPL gels in in vitro studies. Greater AUC was observed with TLP nanoemulsion as compared to TLP gels during in vivo microdialysis. Dermatitis and eczema symptoms were significantly reduced with TPL nanoemulsion gels and can reduce IFN-γ and IL-4 expressions. Obtained results confirm the suitability of nanoemulsion gel as a promising percutaneous carrier to provide low toxicity and prolonged release transdermal formulation for the clinical treatment of AD and eczema.

Nanosuspension

Romero et al. (74) developed a nanosuspension containing cylosporin A (CyA) with the aim to increase dermal penetration. They used wet bead milling technique for the preparation of amorphous nanoparticles. CyA in concentration of 5% w/v was dispersed in water and vitamin E polyethylene glycol succinate (TPGS, Kolliphor TPGS) was added to that dispersion. Average particle size was around 350 nm and D99 (laser diffraction diameter 99%) was 690 nm. Upon storage at room temperature, the suspension was retaining amorphous state for almost 1 year. Hence, it was concluded that the prepared nanosuspension was physically stable. There was reduction of 5% in the total drug content over the span of 1 year but that might be because of a large surface area in contact with water. From that, it was considered that the formulation is feasible as commercial product with expiry date. Micron-sized powder and nanoparticles of CyA were incorporated into HPC gels. Both the formulations were evaluated for penetration and drug retention using fresh pig ear skin, applying the tape stripping method. Micron-sized drug powder showed 71.3 μg/cm2 and nanoparticles of CyA showed 450.1 μg/cm2 which is 6.3 times higher penetration. From the studies on CyA amorphous nanoparticles, dermal nanomedicines delivery seems feasible.

Other than the above discussed formulations, many researchers have worked on the usefulness of different nanomedicines in the topical drug delivery system. They have explored various approaches in the preparation method and delivery systems. Recent development in nanoformulations in the treatment of Atopic dermatitis is summarized in Table III along with advantages of developed formulation by various researchers and few findings are discussed as following.

Table III Example of Nanoformulations for the Treatment of Atopic Dermatitis

EMERGING NANOMATERIALS FOR THE TREATMENT OF AD

Nanoformulations discussed above have the potential to deliver the therapeutic agents topically for the treatment of atopic dermatitis. However, they have many limitations such as low drug loading capacity due to crystalline structure of lipid, polymorphic transition, and lipid particle growth in lipid-based systems (61) and for polymeric systems premature degradation of polymer, aggregation of toxic monomers and residual material associated with them (82).

Emerging formulations such as cubosomes, ethosomes, transferosomes, nanofibers, ionic liquids, nanosponge, and micelles are now being explored for topical drug delivery as the potential solution to the limitations associated with existing formulations. In this section, we have discussed emerging nanomaterials and their applicability in the topical drug delivery.

Cubosomes

Cubosomes are generally prepared using monoolein and are nanoparticle of lipid matrix having inter-crossing water channels with cubic phase and are effective carriers for dermal delivery (83). Liposomes and cubosomes have some common features which includes nano size, feasibility to incorporate water and oil soluble drugs, and they are made up of biocompatible lipids. They have a unique thermodynamic activity which enables loading of water-soluble drug in lipid carrier and as a result skin permeation is enhanced (84,85).

Kwon and Kim (86) developed cubosomes of Houttuynia cordata (HC) to overcome the problem of low skin permeation. The main aim was to enhance the anti-atopic dermatitis effect of aqueous extract of HC (AEHC). AEHC containing cubosomal suspension of monoolein and liposomal suspension of egg phosphotidylcholine were prepared by a thin film hydration method. The skin permeations of AEHC containing cubosomes, lipososmes, and AEHC dissolved in PBS (phosphate buffer saline) were investigated by in vitro method using Franz diffusion cell-mounted hairless mouse skin. Furthermore, 1-chloro-2,4-dinitrobenzene (DNCB) was used to induce AD-like skin lesion in hairless mice and microscopical evaluation was performed to check the inhibitory effects of AEHC-containing formulations. Serum IgE level and cytokine expression were also noted. It was concluded that the cubosomal suspension containing AEHC would be effective treatment for AD.

Ethosomes

Ethosomes are made up of phospholipids and high concentration of water and alcohol. They are flexible and stable. They have the capability to penetrate stratum corneum and deliver therapeutic moiety into deep skin and/or blood. It has been reported that ethosomes are safe, enhance drug efficiency, improve patient compliance, and display cost-effective treatment. The ethosomes can lead to dermatitis or skin irritation due the high ethanol concentration. Nevertheless, Paolini et al. (87) reported that ethosomes demonstrated better skin tolerability in human volunteers with 45% of ethanol in the formulation, for 48 h. Additionally, ethanol is responsible for decrease in density of the lipid multilayer of cell membranes and elevate the fluidity of cell membrane lipids leading to improved skin permeability. Thus, it can penetrate to the deeper layers of the skin where they fuse with the lipids of the skin and release therapeutic moiety.

Nanofibres

Chitin nanofibril (CNF) application was explored as upcoming technology by Azuma et al. (88) on an experimental AD model. CNF showed the anti-inflammatory effects via activation of nuclear factor-kappa B and inducible nitric oxide synthase suppression. It may be concluded that CNF is a potential functional biomaterial for suppression of AD.

Transferosomes

Transferosomes is commonly known as ultra-deformable liposomes and has lot of advantages over liposomes such as high vesicle deformability and elasticity and superior penetration capability. Thus, this system can be explored and can be suited for transdermal or/and dermal delivery with deliberate and controlled release of therapeutic moiety. It has been reported that transferosomes have an ability to transfer 0.1 mg lipid per hour per cm2 area across undamaged skin, which is owing to the osmotic gradient generated by the difference in water content of the striatum corneum (15%) and the viable epidermis (75%). Furthermore, transferosomes have been proposed as a penetration enhancer facilitating entry of drugs through the stratum corneum by disruption of highly ordered lipid structure.

Lei et al. (89) developed tacrolimus-loaded transferosomes for the treatment of atopic dermatitis. Prepared transferosomes were compared with commercial ointment and liposomal gel of the tacrolimus. Surfactants like disodium cholate, Tween 80, and Span 80 were explored for the preparation of transferosomes, out of which Tween 80 showed best results for deformability and drug loading. Percentage entrapment was different with all the surfactants. Maximum entrapment into transferosomes was achieved with Span 80 (83.88%). With Tween 80 and SDC, it was (78.86%) and (70.60%) respectively. Mean particle sizes of transferosomes were 135.6, 123.1, and 260.6 nm with SDC, Tween 80, and Span 80 respectively, where mean particle size of liposomes was 159.7 nm. Transferosomes and other lipid-based vesicles can be differentiated by deformability. Transferosomes spontaneously deform without breaking the structure off lipid when stress is applied on vesicles to penetrate the skin pores. The achieved deformability of transferosomes was the 1.4–2.1 times higher than that of the liposomes and retention levels in skin was 1.2–1.6 times higher. Biphasic drug release was observed from transferosome gel and liposome gel, where initial burst release may be observed from the surface-adsorbed drug and the slower release may be from the lipid vesicles (90). The cumulative drug release after 24 h from transferosome gel, liposome gel, and ointment were (116.72–7.49) μg, (95.75–5.89) μg, and (41.34–3.59) μg respectively. In vivo experiments were performed using mice model of atopic dermatitis and the results from those experiments were in support of in vitro studies. Transferosome gel showed quicker effect than liposome gel and commercial ointment. Ear swelling was reduced, and skin pathology was also improved markedly. Hence, transferosomes can be considered as one of the useful carriers for dermal delivery to treat for atopic dermatitis.

Ionic Liquids

Ionic liquids (IL) are salts composed with relatively large asymmetric organic cations and inorganic or organic anions and having melting point lower than the boiling point of water. They have the capability to dissolve polymeric, organic, and inorganic materials and possess high thermal stability (91). ILs with specific physical or chemical properties can be synthesized by variation of alkyl chain length or cationic structure (92,93). Since the past decade, ILs have gained interest to be explored in pharmaceutical applications as they have been found to be useful for solubility enhancement of the poorly soluble drugs (94,95). Because of their property, ILs can be used for drug delivery via topical route as well.

Dobler et al. (96) explored the use of ionic liquids as different additives in the topical drug delivery system. They used hydrophilic IL [HMIM] [Cl] and the hydrophobic IL [BMIM] [PF6] for the preparation of oil-in-water (O/W) and water-in-oil (W/O) emulsions. Prepared formulations were evaluated for the influence of the ILs on emulsion properties. They found that formulations remain stable after incorporation of ILs into emulsion structure. Formulations showed good antimicrobial activity and preservation efficacy in the concentration range above 5%. Overall, they found that ILs are safe and show improved penetration if used as carriers for topical drug delivery.

Mitragotri et al. (97) studied delivery of therapeutic RANi moieties robed with ionic liquid for treating the skin diseases. They showed that synthesis of robed siRNAs was a simple two-step process from bulk materials. Essential properties like skin transport, octanol water partitioning, and cell internalization for the dermal delivery of siRNA were tuneable with robing. They evaluated the safety and efficacy of robed siRNA by studying its potential to limit the breakdown of elastin in human skin tissues after UVB exposure. They concluded that therapeutic RNAi robed with ionic liquid moieties are a simple, scalable prodrug platform for treating skin disease.

Nanosponge

Iriventi et al. (98) developed a topical gel loaded with nanosponge of curcumin and caffeine. The formulation was prepared by hot melt method using dimethyl carbonate (DMC) as and beta-cyclodextrin (β-CD) as crosslinker and polymer respectively. Curcumin- and caffeine-loaded nanosponge-based gel showed better therapeutic effect in comparison with the conventional marketed formulation. The aim behind the preparation of nanosponge and loading them in gel was to achieve sustained release of the drug and that was fulfilled as the formulation showed drug release up to 12 h. In vitro results were supported by in vivo studies and ex vivo permeation studies. It was concluded that nanosponge-loaded gel formulation has higher potential to alleviate psoriasis and thus can be explored for other skin diseases which involves inflammatory responses and may be proposed as a promising carrier for an effective local treatment.

Abbas et al. (99) explored fluconazole-loaded nanosponge-based hydrogel system for improved topical delivery. The prepared nanosponge was evaluated for their entrapment efficiency, particle size, structural properties, and in vitro drug release. Release pattern indicated the sustained release of fluconazole from hydrogel and showed Higuchi model as the best fit model. Key advantages of nanosponge are better retention, reduced systemic side effects and dosing frequency which makes it potentially suitable for the treatment and improve patient compliance.

Micelles

Assem et al. (100) developed polymeric micelles of beclomethasone dipropionate and incorporated them into biocompatible hydrogel. The formulation was evaluated using sub-chronic dermatitis animal model. Mixed micelles intended to target dermal delivery were prepared. Various concentrations of pluronic L121 were used with either poloxamer P84 or poloxamer 407. Micelles were incorporated into hydrogels and evaluated for viscosity and was also subjected to ex vivo skin permeation study in comparison with marketed cream Beclozone®. In vivo studies were performed using rat model and results of histopathology of the skin showed that the prepared micelles are more effective in treating atopic dermatitis as compared to the Beclozone®. Hence, micelles can be considered as promising drug delivery in the treatment of skin diseases.

Lapteva et al. (101) developed polymeric micelles of Tacrolimus (FK506) for the treatment of psoriasis. Polymeric micelles were prepared using biodegradable and biocompatible methoxypoly(ethylene glycol)-dihexyl-substituted polylactide (MPEG-dihex-PLA) diblock copolymer and the results proved the efficiency of MPEG-dihexPLA micelles for the selective cutaneous delivery of FK506, superior to the marketed formulation (Protopic). Since the FK506 is prescribed for atopic dermatitis, this formulation can be explored for AD as well.

Although emerging nanomaterials are not widely explored for the treatment of atopic dermatitis, their potential for topical drug delivery is quite promising. Hence, they possess bright future to be explored for the treatment of AD.

FUTURE OF AD USING NANOMEDICINE

Nanomedicines are beneficial in achieving the desired rate of release and the skin targeting by modifying permeation and penetration of active substances. Improved retention in the skin ensures a drug localization in the stratum corneum and protection of drug against chemical or physical changes. Furthermore, maintenance of normal skin barrier function is essential while delivering the therapeutic agents. Use of chemical enhancers like surfactants and organic solvents may be responsible for reduction in the barrier function along with higher skin irritancy/damage.

Nanoparticle-based drug delivery systems is beneficial in overcoming the limitations and adverse effects of existing delivery system by enhancing the local effect. Researchers have a big challenge in front of them for identifying a suitable approach for exponential growth in AD and other skin diseases. Literature indicates enormous work explored by scientists on the potential use of antibiotics, corticosteroids, calcineurin inhibitors, and few natural polyphenolic compounds after suitable incorporation into carrier systems for effective treatment of AD. The research output is promising in treating AD effectively. However, there are few challenges like toxicity of the nanomedicines, dose determination, and cost effectiveness that are still to be resolved.

CONCLUSION

Nanomedicine is offering various opportunities in the field of research and business and it is representing the crucial technology development in the twenty-first century (102). There are many nanotechnology-based cosmeceutical products capturing the market and potential of products for AD is being proven at the research level. However, there are several emerging nanocarriers such as ionic liquids (103), silica nanoparticles (104), plant- and milk-based proteins, and silicon nanoparticles (105), which are already explored for oral delivery and holds enormous potential for topical delivery of peptides, proteins, and poorly soluble and permeable small molecules (106). Their untapped potential needs to be investigated in detail.

Nanomedicines have capability to minimize dosing frequency, achieve effective therapeutic concentration, reduce side effects, and improve patient compliance with targeted delivery of many drugs peptides and proteins. However, there is a great need for detailed investigation on the usefulness of NPs as substantial carrier for topical administration and its distribution in the skin particularly when used with the topical gel or cream. With the development of technology, there is wider scope for linkage between instruments and nanotechnology with greater understanding about easing off the skin diseases by establishing in vitro and in vivo correlation. However, future studies are still necessary to establish its safety and efficacy in order to ensure consumer health.

References

  1. 1.

    Kaltoft K, Pedersen CB, Hansen BH, Lemonidis AS, Frydenberg J, Thestrup-Pedersen K. In vitro genetically aberrant T cell clones with continuous growth are associated with atopic dermatitis. Arch Dermatol Res. 1994;287(1):42–7.

    CAS  PubMed  Google Scholar 

  2. 2.

    Lee H, Suh SS, Park E, Cho E, Ahn JH, Kim SG, et al. The AGAMOUS-LIKE 20 MADS domain protein integrates floral inductive pathways in Arabidopsis. Genes Dev. 2000;14(18):2366–76.

    CAS  PubMed  PubMed Central  Google Scholar 

  3. 3.

    Vandita K, Manoj K, Komal S. An overview of atopic dermatitis with a focus on nano-interventions. EMJ Innov. 2019;3(1):44–54.

    Google Scholar 

  4. 4.

    Gaspar NK, Aidé MK. Atopic dermatitis: allergic dermatitis or neuroimmune dermatitis? An Bras Dermatol. 2016;91(4):479–88.

    PubMed  PubMed Central  Google Scholar 

  5. 5.

    Thomsen SF. Atopic dermatitis: natural history, diagnosis, and treatment. ISRN Allergy. 2014;2014:1–7.

    Google Scholar 

  6. 6.

    Eichenfield LF, Ellis CN, Mancini AJ, Paller AS, Simpson EL. Atopic dermatitis: epidemiology and pathogenesis update. Semin Cutan Med Surg. 2012;31(3):S3–5.

    CAS  PubMed  Google Scholar 

  7. 7.

    Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66(1):8–16.

    CAS  PubMed  Google Scholar 

  8. 8.

    Karimkhani Aksut C, Dellavalle RP, Naghavi M. 181 Global skin disease morbidity and mortality: an update from the Global Burden of Disease Study 2013. J Invest Dermatol. 2017;137(5):S31.

    Google Scholar 

  9. 9.

    Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345–60.

    CAS  PubMed  Google Scholar 

  10. 10.

    DaVeiga SP. Epidemiology of atopic dermatitis: a review. Allergy Asthma Proc. 2012;33(3):227–34.

    PubMed  Google Scholar 

  11. 11.

    Asher MI, Montefort S, Björkstén B, Lai CK, Strachan DP, Weiland SK, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006;368(9537):733–43.

    PubMed  PubMed Central  Google Scholar 

  12. 12.

    Williams HC. Atopic dermatitis. N Engl J Med. 2005;352(22):2314–24.

    CAS  PubMed  Google Scholar 

  13. 13.

    Dhar S, Kanwar AJ. Epidemiology and clinical pattern of atopic dermatitis in a North Indian pediatric population. Pediatr Dermatol. 1998;15(5):347–51.

    CAS  PubMed  Google Scholar 

  14. 14.

    Spergel JM. From atopic dermatitis to asthma: the atopic march. Ann Allergy. Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol. 2010;105(2):99–106 quiz 107–9, 117.

    CAS  Google Scholar 

  15. 15.

    Lowe AJ, Carlin JB, Bennett CM, Hosking CS, Abramson MJ, Hill DJ, et al. Do boys do the atopic march while girls dawdle? J Allergy Clin Immunol. 2008;121(5):1190–5.

    PubMed  Google Scholar 

  16. 16.

    Thomsen SF, Ulrik CS, Kyvik KO, Hjelmborg J. v B, Skadhauge LR, Steffensen I, et al. Importance of genetic factors in the etiology of atopic dermatitis: a twin study. Allergy Asthma Proc. 2007;28(5):535–9.

    PubMed  Google Scholar 

  17. 17.

    Thomsen SF. The contribution of twin studies to the understanding of the aetiology of asthma and atopic diseases. Eur Clin Respir J [Internet]. 2015 Sep 11 [cited 2019 Jul 15];2. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4653279/

  18. 18.

    Ahn K, Kim BE, Kim J, Leung DY. Recent advances in atopic dermatitis. Curr Opin Immunol. 2020;66:14–21.

    CAS  PubMed  Google Scholar 

  19. 19.

    Eyerich K, Novak N. Immunology of atopic eczema: overcoming the Th1/Th2 paradigm. Allergy. 2013;68(8):974–82.

    CAS  PubMed  Google Scholar 

  20. 20.

    Palmer CNA, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006;38(4):441–6.

    CAS  PubMed  Google Scholar 

  21. 21.

    Nakai K, Yoneda K, Maeda R, Munehiro A, Fujita N, Yokoi I, et al. Urinary biomarker of oxidative stress in patients with psoriasis vulgaris and atopic dermatitis. J Eur Acad Dermatol Venereol JEADV. 2009;23(12):1405–8.

    CAS  PubMed  Google Scholar 

  22. 22.

    Cork MJ, Robinson DA, Vasilopoulos Y, Ferguson A, Moustafa M, MacGowan A, et al. New perspectives on epidermal barrier dysfunction in atopic dermatitis: gene-environment interactions. J Allergy Clin Immunol. 2006;118(1):3–21 quiz 22–3.

    CAS  PubMed  Google Scholar 

  23. 23.

    Elias PM, Hatano Y, Williams ML. Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms. J Allergy Clin Immunol. 2008;121(6):1337–43.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. 24.

    Nemoto-Hasebe I, Akiyama M, Nomura T, Sandilands A, McLean WHI, Shimizu H. Clinical severity correlates with impaired barrier in filaggrin-related eczema. J Invest Dermatol. 2009;129(3):682–9.

    CAS  PubMed  Google Scholar 

  25. 25.

    Katoh N. Future perspectives in the treatment of atopic dermatitis. J Dermatol. 2009;36(7):367–76.

    CAS  PubMed  Google Scholar 

  26. 26.

    Katayama I, Aihara M, Ohya Y, Saeki H, Shimojo N, Shoji S, et al. Japanese guidelines for atopic dermatitis 2017. Allergol Int. 2017;66(2):230–47.

    PubMed  Google Scholar 

  27. 27.

    Leung DY, Harbeck R, Bina P, Reiser RF, Yang E, Norris DA, et al. Presence of IgE antibodies to staphylococcal exotoxins on the skin of patients with atopic dermatitis. Evidence for a new group of allergens. J Clin Invest. 1993;92(3):1374–80.

    CAS  PubMed  PubMed Central  Google Scholar 

  28. 28.

    Scharschmidt TC, Segre JA. Modeling atopic dermatitis with increasingly complex mouse models. J Invest Dermatol. 2008;128(5):1061–4.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. 29.

    Bouwstra JA, de Graaff A, Gooris GS, Nijsse J, Wiechers JW, van Aelst AC. Water distribution and related morphology in human stratum corneum at different hydration levels. J Invest Dermatol. 2003;120(5):750–8.

    CAS  PubMed  Google Scholar 

  30. 30.

    Pople PV, Singh KK. Development and evaluation of colloidal modified nanolipid carrier: application to topical delivery of tacrolimus. Eur J Pharm Biopharm. 2011;79(1):82–94.

    CAS  PubMed  Google Scholar 

  31. 31.

    Snijders BEP, Thijs C, van Ree R, van den Brandt PA. Age at first introduction of cow milk products and other food products in relation to infant atopic manifestations in the first 2 years of life: the KOALA Birth Cohort Study. Pediatrics. 2008;122(1):e115–22.

    PubMed  Google Scholar 

  32. 32.

    Dunlop AL, Reichrtova E, Palcovicova L, Ciznar P, Adamcakova-Dodd A, Smith SJ, et al. Environmental and dietary risk factors for infantile atopic eczema among a Slovak birth cohort. Pediatr Allergy Immunol Off Publ Eur Soc Pediatr Allergy Immunol. 2006;17(2):103–11.

    Google Scholar 

  33. 33.

    Rowlands D, Tofte SJ, Hanifin JM. Does food allergy cause atopic dermatitis? Food challenge testing to dissociate eczematous from immediate reactions. Dermatol Ther. 2006;19(2):97–103.

    PubMed  Google Scholar 

  34. 34.

    Akdis CA, Akdis M, Bieber T, Bindslev-Jensen C, Boguniewicz M, Eigenmann P, et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. J Allergy Clin Immunol. 2006;118(1):152–69.

    PubMed  Google Scholar 

  35. 35.

    Saeki H, Furue M, Furukawa F, Hide M, Ohtsuki M, Katayama I, et al. Guidelines for management of atopic dermatitis. J Dermatol. 2009;36(10):563–77.

    PubMed  Google Scholar 

  36. 36.

    Katoh N, Hirano S, Kishimoto S. Prognostic factor of adult patients with atopic dermatitis. J Dermatol. 2008;35(8):477–83.

    PubMed  Google Scholar 

  37. 37.

    Drugs@FDA: FDA Approved Drug Products [Internet]. [cited 2019 Jul 18]. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/

  38. 38.

    Ellis CN, Mancini AJ, Paller AS, Simpson EL, Eichenfield LF. Understanding and managing atopic dermatitis in adult patients. Semin Cutan Med Surg. 2012;31(3):S18–22.

    CAS  PubMed  Google Scholar 

  39. 39.

    Home - ClinicalTrials.gov [Internet]. [cited 2020 Aug 9]. Available from: https://clinicaltrials.gov/

  40. 40.

    Coondoo A, Phiske M, Verma S, Lahiri K. Side-effects of topical steroids: a long overdue revisit. Indian Dermatol Online J. 2014;5(4):416–25.

    PubMed  PubMed Central  Google Scholar 

  41. 41.

    Yamamoto T, Matsunaga T, Nishioka K. Rheumatoid neutrophilic dermatitis, rheumatoid papules, and rheumatoid nodules in a patient with seronegative rheumatoid arthritis. J Am Acad Dermatol. 2003;48(4):634–5.

    PubMed  Google Scholar 

  42. 42.

    Patel A, Patel M, Yang X, Mitra AK. Recent advances in protein and peptide drug delivery: a special emphasis on polymeric nanoparticles. Protein Pept Lett. 2014;21(11):1102–20.

    CAS  PubMed  PubMed Central  Google Scholar 

  43. 43.

    Mocan T, Matea CT, Iancu C, Agoston-Coldea L, Mocan L, Orasan R. Hypersensitivity and nanoparticles: update and research trends. Clujul Med. 2016;89(2):216–9.

    PubMed  PubMed Central  Google Scholar 

  44. 44.

    Iqbal MA, Md S, Sahni JK, Baboota S, Dang S, Ali J. Nanostructured lipid carriers system: recent advances in drug delivery. J Drug Target. 2012;20(10):813–30.

    CAS  PubMed  Google Scholar 

  45. 45.

    Nastiti CMRR, Ponto T, Abd E, Grice JE, Benson HAE, Roberts MS. Topical nano and microemulsions for skin delivery. Pharmaceutics [Internet]. 2017 Sep 21 [cited 2020 Sep 7];9(4). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5750643/

  46. 46.

    Charman WN, Stella VJ. Transport of lipophilic molecules by the intestinal lymphatic system. Adv Drug Deliv Rev. 1991;7(1):1–14.

    CAS  Google Scholar 

  47. 47.

    Karuppagounder V, Arumugam S, Thandavarayan RA, Sreedhar R, Giridharan VV, Watanabe K. Molecular targets of quercetin with anti-inflammatory properties in atopic dermatitis. Drug Discov Today. 2016;21(4):632–9.

    CAS  PubMed  Google Scholar 

  48. 48.

    Zeb A, Arif ST, Malik M, Shah FA, Din FU, Qureshi OS, et al. Potential of nanoparticulate carriers for improved drug delivery via skin. J Pharm Investig. 2019;49(5):485–517.

    Google Scholar 

  49. 49.

    Zhuo F, Abourehab MAS, Hussain Z. Hyaluronic acid decorated tacrolimus-loaded nanoparticles: efficient approach to maximize dermal targeting and anti-dermatitis efficacy. Carbohydr Polym. 2018;197:478–89.

    CAS  PubMed  Google Scholar 

  50. 50.

    Pandey M, Choudhury H, Gunasegaran TAP, Nathan SS, Md S, Gorain B, et al. Hyaluronic acid-modified betamethasone encapsulated polymeric nanoparticles: fabrication, characterisation, in vitro release kinetics, and dermal targeting. Drug Deliv Transl Res. 2019;9(2):520–33.

    CAS  PubMed  Google Scholar 

  51. 51.

    Try C, Moulari B, Béduneau A, Fantini O, Pin D, Pellequer Y, et al. Size dependent skin penetration of nanoparticles in murine and porcine dermatitis models. Eur J Pharm Biopharm. 2016;100:101–8.

    CAS  PubMed  Google Scholar 

  52. 52.

    Siddique MI, Katas H, Jamil A, Mohd Amin MCI, Ng S-F, Zulfakar MH, et al. Potential treatment of atopic dermatitis: tolerability and safety of cream containing nanoparticles loaded with hydrocortisone and hydroxytyrosol in human subjects. Drug Deliv Transl Res. 2019;9(2):469–81.

    CAS  PubMed  Google Scholar 

  53. 53.

    Sahle FF, Gerecke C, Kleuser B, Bodmeier R. Formulation and comparative in vitro evaluation of various dexamethasone-loaded pH-sensitive polymeric nanoparticles intended for dermal applications. Int J Pharm. 2017;516(1–2):21–31.

    CAS  PubMed  Google Scholar 

  54. 54.

    Fessi H, Puisieux F, Devissaguet JP, Ammoury N, Benita S. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int J Pharm. 1989;55(1):R1–4.

    CAS  Google Scholar 

  55. 55.

    Katas H, Hussain Z, Ling TC. Chitosan nanoparticles as a percutaneous drug delivery system for hydrocortisone. J Nanomater. 2012;2012:372725.

    Google Scholar 

  56. 56.

    Yu K, Wang Y, Wan T, Zhai Y, Cao S, Ruan W, et al. Tacrolimus nanoparticles based on chitosan combined with nicotinamide: enhancing percutaneous delivery and treatment efficacy for atopic dermatitis and reducing dose. Int J Nanomedicine. 2017;13:129–42.

    PubMed  PubMed Central  Google Scholar 

  57. 57.

    Ghosh N, Mitra S, Banerjee ER. Therapeutic effects of topically-administered guar gum nanoparticles in oxazolone-induced atopic dermatitis in mice. Biomedical Research and Therapy. 5(5):2305–25. https://doi.org/10.15419/bmrat.v5i5.444.

  58. 58.

    Rosado C, Silva C, Reis CP. Hydrocortisone-loaded poly(ε-caprolactone) nanoparticles for atopic dermatitis treatment. Pharm Dev Technol. 2013;18(3):710–8.

    CAS  PubMed  Google Scholar 

  59. 59.

    Pople PV, Singh KK. Targeting tacrolimus to deeper layers of skin with improved safety for treatment of atopic dermatitis—Part II: In vivo assessment of dermatopharmacokinetics, biodistribution and efficacy. Int J Pharm. 2012;434(1–2):70–9.

    CAS  PubMed  Google Scholar 

  60. 60.

    Das S, Ng WK, Tan RBH. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs? Eur J Pharm Sci Off J Eur Fed Pharm Sci. 2012;47(1):139–51.

    CAS  Google Scholar 

  61. 61.

    Naseri N, Valizadeh H, Zakeri-Milani P. Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application. Adv Pharm Bull. 2015;5(3):305–13.

    CAS  PubMed  PubMed Central  Google Scholar 

  62. 62.

    Müller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm. 2002;242(1):121–8.

    PubMed  Google Scholar 

  63. 63.

    Tapeinos C, Battaglini M, Ciofani G. Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases. J Control Release. 2017;264:306–32.

    CAS  PubMed  PubMed Central  Google Scholar 

  64. 64.

    Chauhan I, Yasir M, Verma M, Singh AP. nanostructured lipid carriers: a groundbreaking approach for transdermal drug delivery. Adv Pharm Bull. 2020;10(2):150–65.

    CAS  PubMed  PubMed Central  Google Scholar 

  65. 65.

    Siddique MI, Katas H, Amin MCIM, Ng S-F, Zulfakar MH, Jamil A. In-vivo dermal pharmacokinetics, efficacy, and safety of skin targeting nanoparticles for corticosteroid treatment of atopic dermatitis. Int J Pharm. 2016;507(1–2):72–82.

    CAS  PubMed  Google Scholar 

  66. 66.

    Pople PV, Singh KK. Development and evaluation of colloidal modified nanolipid carrier: Application to topical delivery of tacrolimus, Part II – In vivo assessment, drug targeting, efficacy, and safety in treatment for atopic dermatitis. Eur J Pharm Biopharm. 2013;84(1):72–83.

    CAS  PubMed  Google Scholar 

  67. 67.

    Maia CS, Mehnert W, Schäfer-Korting M. Solid lipid nanoparticles as drug carriers for topical glucocorticoids. Int J Pharm. 2000;196(2):165–7.

    CAS  PubMed  Google Scholar 

  68. 68.

    Kong X, Zhao Y, Quan P, Fang L. Development of a topical ointment of betamethasone dipropionate loaded nanostructured lipid carrier. Asian J Pharm Sci. 2016;11(2):248–54.

    Google Scholar 

  69. 69.

    Kang MJ, Eum JY, Park SH, Kang MH, Park KH, Choi SE, et al. Pep-1 peptide-conjugated elastic liposomal formulation of taxifolin glycoside for the treatment of atopic dermatitis in NC/Nga mice. Int J Pharm. 2010;402(1–2):198–204.

    CAS  PubMed  Google Scholar 

  70. 70.

    Baspinar Y, Keck CM, Borchert H-H. Development of a positively charged prednicarbate nanoemulsion. Int J Pharm. 2010;383(1–2):201–8.

    CAS  PubMed  Google Scholar 

  71. 71.

    Lalan MS, Laddha NC, Lalani J, Imran MJ, Begum R, Misra A. Suppression of cytokine gene expression and improved therapeutic efficacy of microemulsion-based tacrolimus cream for atopic dermatitis. Drug Deliv Transl Res. 2012;2(2):129–41.

    CAS  PubMed  Google Scholar 

  72. 72.

    Sarfaraz Alam M, Ali MS, Zakir F, Alam N, Intakhab Alam M, Ahmad F, et al. Enhancement of anti-dermatitis potential of clobetasol propionate by DHA [docosahexaenoic acid] rich algal oil nanoemulsion gel. Iran J Pharm Res IJPR. 2016;15(1):35–52.

    PubMed  Google Scholar 

  73. 73.

    Yang M, Gu Y, Yang D, Tang X, Liu J. Development of triptolide-nanoemulsion gels for percutaneous administration: physicochemical, transport, pharmacokinetic and pharmacodynamic characteristics. J Nanobiotechnology. 2017;15(1):88.

    PubMed  PubMed Central  Google Scholar 

  74. 74.

    Romero GB, Arntjen A, Keck CM, Müller RH. Amorphous cyclosporin A nanoparticles for enhanced dermal bioavailability. Int J Pharm. 2016;498(1–2):217–24.

    CAS  PubMed  Google Scholar 

  75. 75.

    Lohan SB, Saeidpour S, Colombo M, Staufenbiel S, Unbehauen M, Wolde-Kidan A, et al. Nanocrystals for improved drug delivery of dexamethasone in skin investigated by EPR spectroscopy. Pharmaceutics. 2020;12(5):400.

    CAS  PubMed Central  Google Scholar 

  76. 76.

    Haeri A, Osouli M, Bayat F, Alavi S, Dadashzadeh S. Nanomedicine approaches for sirolimus delivery: a review of pharmaceutical properties and preclinical studies. Artif Cells Nanomedicine Biotechnol. 2018;46(sup1):1–14.

    CAS  Google Scholar 

  77. 77.

    Cm K, K S. Silver-nanolipid complex for application to atopic dermatitis skin: rheological characterization, in vivo efficiency and theory of action. Vol. 5, Journal of biomedical nanotechnology. J Biomed Nanotechnol; 2009.

  78. 78.

    Nam S-H, Ji XY, Park J-S. Investigation of tacrolimus loaded nanostructured lipid carriers for topical drug delivery. Bull Kor Chem Soc. 2011;32(3):956–60.

    CAS  Google Scholar 

  79. 79.

    Doktorovová S, Araújo J, Garcia ML, Rakovský E, Souto EB. Formulating fluticasone propionate in novel PEG-containing nanostructured lipid carriers (PEG-NLC). Colloids Surf B: Biointerfaces. 2010;75(2):538–42.

    PubMed  Google Scholar 

  80. 80.

    Doktorovová S, Kovačević AB, Garcia ML, Souto EB. Preclinical safety of solid lipid nanoparticles and nanostructured lipid carriers: current evidence from in vitro and in vivo evaluation. Eur J Pharm Biopharm Off J Arbeitsgemeinschaft Pharm Verfahrenstechnik EV. 2016;108:235–52.

    Google Scholar 

  81. 81.

    Pa H, Mm G. S G. Development of betamethasone dipropionate-loaded nanostructured lipid carriers for topical and transdermal delivery. Anti-Inflamm Anti-Allergy Agents Med Chem. 2019;18(1):26–44.

    Google Scholar 

  82. 82.

    Lockman PR, Mumper RJ, Khan MA, Allen DD. Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev Ind Pharm. 2002;28(1):1–13.

    CAS  PubMed  Google Scholar 

  83. 83.

    Esposito E, Cortesi R, Drechsler M, Paccamiccio L, Mariani P, Contado C, et al. Cubosome dispersions as delivery systems for percutaneous administration of indomethacin. Pharm Res. 2005;22(12):2163–73.

    CAS  PubMed  Google Scholar 

  84. 84.

    Sinico C, Manconi M, Peppi M, Lai F, Valenti D, Fadda AM. Liposomes as carriers for dermal delivery of tretinoin: in vitro evaluation of drug permeation and vesicle–skin interaction. J Control Release. 2005;103(1):123–36.

    CAS  PubMed  Google Scholar 

  85. 85.

    Taek-Kwan Kwon, Hyeon-Yong Lee, Jin-Chul Kim & Baik Hwang. In vitro skin permeation enhancement of asiaticoside by liquid crystal vesicles. Molecular Crystals and Liquid Crystals, 508:1, 191/[553]-199/[561], https://doi.org/10.1080/15421400903060847.

  86. 86.

    Kwon TK, Kim J-C. In vitro skin permeation and anti-atopic efficacy of lipid nanocarriers containing water soluble extracts of Houttuynia cordata. Drug Dev Ind Pharm. 2014;40(10):1350–7.

    CAS  PubMed  Google Scholar 

  87. 87.

    Paolino D, Celia C, Trapasso E, Cilurzo F, Fresta M. Paclitaxel-loaded ethosomes®: Potential treatment of squamous cell carcinoma, a malignant transformation of actinic keratoses. Eur J Pharm Biopharm. 2012;81(1):102–12.

    CAS  PubMed  Google Scholar 

  88. 88.

    Izumi R, Azuma K, Izawa H, Morimoto M, Nagashima M, Osaki T, et al. Chitin nanofibrils suppress skin inflammation in atopic dermatitis-like skin lesions in NC/Nga mice. Carbohydr Polym. 2016;146:320–7.

    CAS  PubMed  Google Scholar 

  89. 89.

    Laouini A, Jaafar-Maalej C, Sfar S, Charcosset C, Fessi H. Liposome preparation using a hollow fiber membrane contactor—application to spironolactone encapsulation. Int J Pharm. 2011;415(1):53–61.

    CAS  PubMed  Google Scholar 

  90. 90.

    Lei W, Yu C, Lin H, Zhou X. Development of tacrolimus-loaded transfersomes for deeper skin penetration enhancement and therapeutic effect improvement in vivo. Asian J Pharm Sci. 2013;8(6):336–45.

    Google Scholar 

  91. 91.

    Huddleston JG, Visser AE, Reichert WM, Willauer HD, Broker GA, Rogers RD. Characterization and comparison of hydrophilic and hydrophobic room temperature ionic liquids incorporating the imidazolium cation. Green Chem. 2001;3(4):156–64.

    CAS  Google Scholar 

  92. 92.

    Tokuda H, Hayamizu K, Ishii K. Susan MdABH, Watanabe M. Physicochemical properties and structures of room temperature ionic liquids. 2. Variation of alkyl chain length in imidazolium cation. J Phys Chem B. 2005;109(13):6103–10.

    CAS  PubMed  Google Scholar 

  93. 93.

    Tokuda H, Ishii K. Susan MdABH, Tsuzuki S, Hayamizu K, Watanabe M. Physicochemical properties and structures of room-temperature ionic liquids. 3. Variation of cationic structures. J Phys Chem B. 2006;110(6):2833–9.

    CAS  PubMed  Google Scholar 

  94. 94.

    Jaitely V, Karatas A, Florence AT. Water-immiscible room temperature ionic liquids (RTILs) as drug reservoirs for controlled release. Int J Pharm. 2008;354(1–2):168–73.

    CAS  PubMed  Google Scholar 

  95. 95.

    Mizuuchi H, Jaitely V, Murdan S, Florence AT. Room temperature ionic liquids and their mixtures: potential pharmaceutical solvents. Eur J Pharm Sci. 2008;33(4):326–31.

    CAS  PubMed  Google Scholar 

  96. 96.

    Dobler D, Schmidts T, Klingenhöfer I, Runkel F. Ionic liquids as ingredients in topical drug delivery systems. Int J Pharm. 2013;441(1–2):620–7.

    CAS  PubMed  Google Scholar 

  97. 97.

    Zakrewsky M, Mitragotri S. Therapeutic RNAi robed with ionic liquid moieties as a simple, scalable prodrug platform for treating skin disease. J Control Release. 2016;242:80–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  98. 98.

    Iriventi P, Gupta NV, Osmani RAM, Balamuralidhara V. Design & development of nanosponge loaded topical gel of curcumin and caffeine mixture for augmented treatment of psoriasis. DARU J Pharm Sci. 2020 May 29.

  99. 99.

    Abbas N, Parveen K, Hussain A, Latif S, Uz Zaman S, Shah PA, et al. Nanosponge-based hydrogel preparation of fluconazole for improved topical delivery. Trop J Pharm Res. 2019;18(2):215.

    CAS  Google Scholar 

  100. 100.

    Assem M, Khowessah OM, Ghorab D. Optimization and evaluation of beclomethasone dipropionate micelles incorporated into biocompatible hydrogel using a sub-chronic dermatitis animal model. AAPS PharmSciTech. 2019;20(4).

  101. 101.

    Lapteva M, Mondon K, Möller M, Gurny R, Kalia YN. polymeric micelle nanocarriers for the cutaneous delivery of tacrolimus: a targeted approach for the treatment of psoriasis. Mol Pharm. 2014;11(9):2989–3001.

    CAS  PubMed  Google Scholar 

  102. 102.

    Martins JP. das Neves J, de la Fuente M, Celia C, Florindo H, Günday-Türeli N, et al. The solid progress of nanomedicine. Drug Deliv Transl Res. 2020;10(3):726–9.

    PubMed  PubMed Central  Google Scholar 

  103. 103.

    Dharamdasani V, Mandal A, Qi QM, Suzuki I, Bentley MVLB, Mitragotri S. Topical delivery of siRNA into skin using ionic liquids. J Control Release. 2020;323:475–82.

    CAS  PubMed  Google Scholar 

  104. 104.

    Abeer MM, Rewatkar P, Qu Z, Talekar M, Kleitz F, Schmid R, et al. Silica nanoparticles: a promising platform for enhanced oral delivery of macromolecules. J Control Release. 2020;326:544–55.

    CAS  PubMed  Google Scholar 

  105. 105.

    Pujara N, Wong KY, Qu Z, Wang R, Moniruzzaman Md, Rewatkar P, et al. Oral delivery of β-lactoglobulin-nanosphere-encapsulated resveratrol alleviates inflammation in winnie mice with spontaneous ulcerative colitis. Mol Pharm. 2020.

  106. 106.

    Ndayishimiye J, Popat A, Blaskovich M, Falconer JR. Formulation technologies and advances for oral delivery of novel nitroimidazoles and antimicrobial peptides. J Control Release. 2020;324:728–49.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

Authors are thankful to Institute of Pharmacy, Nirma University, for providing facilities and support. Authors would like to thank DST, SERB, CII, Government of India, and CSIR for providing financial assistances in the form of Prime Minister’s Fellowship and CSIR-SRF Fellowship respectively to Khushali Parekh (D.O. No SERB/PM Fellow/CII-FICCI/Meeting/2018 dated 27/02/2018 and Namdev Dhas (09/1048(007)/2018-EMR-I. Dr. Popat would like to thank NHMRC for Early and Career Development Fellowship.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Tejal A Mehta.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Parekh, K., Mehta, T.A., Dhas, N. et al. Emerging Nanomedicines for the Treatment of Atopic Dermatitis. AAPS PharmSciTech 22, 55 (2021). https://doi.org/10.1208/s12249-021-01920-3

Download citation

KEY WORDS

  • nanomedicines
  • atopic dermatitis
  • topical drug delivery
  • skin targeting
  • novel formulations